Disclosed are compounds of formula I: ##STR00001## as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

Homeopathic spray, gel, and rinse compositions containing tinctures of Arnica montana, Calendula officinalis, Chamomilla, Ignatia amara, Echinacea purpurea and/or Echinacea angustifolia are disclosed, along with homeopathic compositions containing tinctures of Calendula officinalis, Echinacea purpurea, Plantago major, and Azadirachta indica. Methods of using, and kits containing, the homeopathic spray, gel, rinse and other compositions for maintaining oral care and reducing inflammation, pain, and bruising after oral surgery are provided.

This invention relates to a formulation comprising a proteinaceous microgel and one or more biopolymeric nanofibrils. The invention also relates to methods for preparing such formulations. The invention also contemplates the uses of the formulations.

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

A class of bifunctional compounds for targeting and degrading an IRAK4 kinase protein, a pharmaceutical composition and a preparation method therefor are provided. The compounds not only effectively inhibits and/or degrades the IRAK4 kinase protein in cells, but also effectively inhibit the production of IL-6 by immune cells, and has good degradation selectivity. The compounds can be used in the preparation of a drug for treating and/or preventing IRAK4-mediated related diseases or conditions, such as cancer, immunological diseases and inflammatory diseases.

A novel prophylactic agent or therapeutic agent for functional gastrointestinal disorders or xerostomia is provided. The present invention is a therapeutic agent or prophylactic agent for functional gastrointestinal disorders, containing an azabenzimidazole compound represented by the following formula [1] (each symbol in the formula is as described in the specification), or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.

##STR00001##

A composition having molecular iodine in combination with a polyol can be used for control and treatment of microbes and infections on biological and non-biological surfaces. Compositions have a combination of molecular iodine (I2) and an acceptable source of iodate (IO3), and a buffering acid (inorganic or organic), in combination with a polyol in an amount of 3-50% by weight. The present compositions can also have prebiotic and probiotic properties on biological surfaces and membranes for the control and treatment of infection as well as the support of growth of commensal microbes and the control of pathogenic microbes.